PHILADELPHIA and LONDON, Dec. 13 /PRNewswire-FirstCall/ --
GlaxoSmithKline (GSK) plc today presented an overview of its neuroscience
portfolio and the company's disease area strategy to investors and analysts
at a meeting in New York.
Highlights
-- Innovative neuroscience pipeline spans 13 different disease areas
including Alzheimer's disease, depression, schizophrenia, and multiple
sclerosis (MS):
- More than 25 innovative compounds currently in development with 15
new mechanisms of action
-- New "proof of concept" data presented on promising phase II compounds
773812 for schizophrenia and 742457 for Alzheimer's disease:
- Both assets to progress to large-scale phase IIb trials assessing
efficacy and safety compared to leading marketed therapies
-- Phase II program for use of ofatumumab in multiple sclerosis
announced, with trials involving approximately 300 patients starting in
2008:
-- Phase III treatment, 1838262, profiled:
- Filing for restless legs syndrome (RLS) expected in third quarter of
2008
- New phase III program for migraine prophylaxis planned
- New phase II studies in neuropathic pain announced
-- Four CNS products with potential to be launched or approved in 2008:
- Trexima potential "new gold standard" for migraine;
- Lamictal XR new once daily treatment for epilepsy;
- Lunivia, a successful treatment for insomnia in the US, expected to
be launched in Europe;
- Requip XL the first non-ergot once daily dopamine agonist for the
treatment of Parkinson's disease
-- Overall pipeline progress continues:
- 8 approvals, 8 filings and 9 key assets starting phase III trials so
far in 2007
- GSK confirms FDA filing of Promacta, a new oral treatment for short-
'/>"/>| SOURCE GlaxoSmithKline Copyright©2007 PR Newswire. All rights reserved |